Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Mori Y, Uchida N, Harada T, Katayama Y, Wake A, Iwasaki H, Eto T, Morishige S, Fujisaki T, Ito Y, Kamimura T, Takahashi T, Imamura Y, Tanimoto K, Ishitsuka K, Sugita J, Kawano N, Tanimoto K, Yoshimoto G, Choi I, Hidaka T, Ogawa R, Takamatsu Y, Miyamoto T, Akashi K, Nagafuji K. Mori Y, et al. Among authors: choi i. Am J Hematol. 2023 Jan;98(1):102-111. doi: 10.1002/ajh.26769. Epub 2022 Oct 31. Am J Hematol. 2023. PMID: 36260658 Free PMC article.
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
Miyamoto T, Yoshimoto G, Kamimura T, Muta T, Takashima S, Ito Y, Shiratsuchi M, Choi I, Kato K, Takenaka K, Iwasaki H, Takamatsu Y, Teshima T, Akashi K. Miyamoto T, et al. Among authors: choi i. Int J Hematol. 2013 Sep;98(3):337-45. doi: 10.1007/s12185-013-1402-0. Epub 2013 Jul 23. Int J Hematol. 2013. PMID: 23877150 Clinical Trial.
Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma.
Mori Y, Choi I, Yoshimoto G, Muta T, Yamasaki S, Tanimoto K, Kamimura T, Iwasaki H, Ogawa R, Akashi K, Miyamoto T; Fukuoka Blood and Marrow Transplantation Group. Mori Y, et al. Among authors: choi i. Int J Hematol. 2020 May;111(5):673-680. doi: 10.1007/s12185-020-02833-w. Epub 2020 Jan 24. Int J Hematol. 2020. PMID: 31981096 Clinical Trial.
Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma.
Yamasaki S, Yoshida S, Kato K, Choi I, Imamura Y, Kohno K, Henzan H, Tanimoto K, Ogawa R, Suehiro Y, Miyamoto T, Eto T, Ohshima K, Akashi K, Iwasaki H; Fukuoka Blood and Marrow Transplantation Group. Yamasaki S, et al. Among authors: choi i. Int J Hematol. 2020 Jul;112(1):74-83. doi: 10.1007/s12185-020-02879-w. Epub 2020 Apr 15. Int J Hematol. 2020. PMID: 32297159
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Takamatsu Y, Sunami K, Hata H, Nagafuji K, Choi I, Higuchi M, Uozumi K, Masaki Y, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Among authors: choi i. Int J Hematol. 2010 Oct;92(3):503-9. doi: 10.1007/s12185-010-0673-y. Epub 2010 Sep 8. Int J Hematol. 2010. PMID: 20824401 Clinical Trial.
Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Yoshimitsu M, Tanosaki R, Kato K, Ishida T, Choi I, Takatsuka Y, Fukuda T, Eto T, Hidaka M, Uchida N, Miyamoto T, Nakashima Y, Moriuchi Y, Nagafuji K, Miyazaki Y, Ichinohe T, Takanashi M, Atsuta Y, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Yoshimitsu M, et al. Among authors: choi i. Biol Blood Marrow Transplant. 2018 Apr;24(4):832-839. doi: 10.1016/j.bbmt.2017.11.005. Epub 2017 Nov 16. Biol Blood Marrow Transplant. 2018. PMID: 29155320 Free article. Clinical Trial.
Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey.
Kato K, Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y, Miyazaki Y, Nakamae H, Oku E, Murata M, Eto T, Akashi K, Sakamaki H, Kato K, Suzuki R, Yamanaka T, Utsunomiya A. Kato K, et al. Among authors: choi i. Biol Blood Marrow Transplant. 2014 Dec;20(12):1968-74. doi: 10.1016/j.bbmt.2014.08.012. Epub 2014 Aug 27. Biol Blood Marrow Transplant. 2014. PMID: 25172635 Free article. Clinical Trial.
Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study.
Ito A, Nakano N, Tanaka T, Fuji S, Makiyama J, Inoue Y, Choi I, Nakamae H, Nagafuji K, Takase K, Machida S, Takahashi T, Sawayama Y, Kamimura T, Kato K, Kawakita T, Ogata M, Sakai R, Shiratori S, Uchimaru K, Inamoto Y, Utsunomiya A, Fukuda T. Ito A, et al. Among authors: choi i. Blood Adv. 2021 Oct 26;5(20):4156-4166. doi: 10.1182/bloodadvances.2021004932. Blood Adv. 2021. PMID: 34500464 Free PMC article.
Effects of Prophylactic Foscarnet on Human Herpesvirus-6 Reactivation and Encephalitis in Cord Blood Transplant Recipients: A Prospective Multicenter Trial with an Historical Control Group.
Ogata M, Takano K, Moriuchi Y, Kondo T, Ueki T, Nakano N, Mori T, Uoshima N, Nagafuji K, Yamasaki S, Shibasaki Y, Sakai R, Kato K, Choi I, Jo Y, Eto T, Kako S, Oshima K, Fukuda T. Ogata M, et al. Among authors: choi i. Biol Blood Marrow Transplant. 2018 Jun;24(6):1264-1273. doi: 10.1016/j.bbmt.2018.02.008. Epub 2018 Feb 15. Biol Blood Marrow Transplant. 2018. PMID: 29454651 Free article. Clinical Trial.
5,281 results